Advertisement

Advertisement

RGNX Stock Latest News

RegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target

RatingsRegenXBio: Advancing Gene Therapy Pipeline and De-Risking Milestones Support Buy Rating and Unchanged $26 Price Target

Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial

PremiumCompany Announcements

Regenxbio Advances Diabetic Retinopathy Gene Therapy Trial

10d ago

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

PremiumThe Fly

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

10d ago

RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained

PremiumRatings

RegenXBio: Advancing Late-Stage RGX-202 and Navsunli Programs Underpin Buy Rating, $16 Price Target Maintained

14d ago

Regenxbio completes dosing in confirmatory study of RGX-202

PremiumThe Fly

Regenxbio completes dosing in confirmatory study of RGX-202

15d ago

Regenxbio price target raised to $32 from $27 at Baird

PremiumThe FlyRegenxbio price target raised to $32 from $27 at Baird

16d ago

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

The Fly

H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission

17d ago

Morning Movers: Getty Images skyrockets after OpenAI deal

The Fly

Morning Movers: Getty Images skyrockets after OpenAI deal

17d ago

Video: SpaceX dips after notes offering, KeyBanc initiation

PremiumThe Fly

Video: SpaceX dips after notes offering, KeyBanc initiation

17d ago

Regenxbio aligns with FDA on path forward for Navsunli

PremiumThe Fly

Regenxbio aligns with FDA on path forward for Navsunli

17d ago

Regenxbio up 25% after saying FDA will reverse rejection, consider application

PremiumThe Fly

Regenxbio up 25% after saying FDA will reverse rejection, consider application

17d ago

Regenxbio tells WSJ that FDA will reverse rejection of drug

PremiumThe Fly

Regenxbio tells WSJ that FDA will reverse rejection of drug

17d ago

Regenxbio price target lowered to $26 from $30 at H.C. Wainwright

PremiumThe FlyRegenxbio price target lowered to $26 from $30 at H.C. Wainwright

1M ago

Acting FDA head vows to block political interference, Endpoint News says

The Fly

Acting FDA head vows to block political interference, Endpoint News says

1M ago

RegenXBio Launches Targeted Employee Stock Option Exchange

Company Announcements

RegenXBio Launches Targeted Employee Stock Option Exchange

1M ago

FDA issues draft guidance to help accelerated cell, gene therapies for patients

PremiumThe Fly

FDA issues draft guidance to help accelerated cell, gene therapies for patients

1M ago

RegenXbio’s RGX-202 Pivotal Win Lifts Outlook

PremiumCompany Announcements

RegenXbio’s RGX-202 Pivotal Win Lifts Outlook

2M ago

RegenXBio’s Earnings Call Signals Pivotal Gene-Therapy Win

PremiumCompany Announcements

RegenXBio’s Earnings Call Signals Pivotal Gene-Therapy Win

2M ago

Regenxbio price target lowered to $16 from $17 at Morgan Stanley

PremiumThe Fly

Regenxbio price target lowered to $16 from $17 at Morgan Stanley

2M ago

Regenxbio price target lowered to $14 from $25 at BofA

PremiumThe FlyRegenxbio price target lowered to $14 from $25 at BofA

2M ago

Regenxbio price target lowered to $12 from $37 at Barclays

The Fly

Regenxbio price target lowered to $12 from $37 at Barclays

2M ago

Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips

The Fly

Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >